92.59
price up icon2.67%   2.41
after-market Handel nachbörslich: 92.37 -0.22 -0.24%
loading
Schlusskurs vom Vortag:
$90.18
Offen:
$91.34
24-Stunden-Volumen:
2.40M
Relative Volume:
1.25
Marktkapitalisierung:
$18.08B
Einnahmen:
$4.58B
Nettoeinkommen (Verlust:
$870.87M
KGV:
21.05
EPS:
4.3988
Netto-Cashflow:
$945.58M
1W Leistung:
+3.67%
1M Leistung:
+10.37%
6M Leistung:
+53.22%
1J Leistung:
+25.24%
1-Tages-Spanne:
Value
$91.19
$94.62
1-Wochen-Bereich:
Value
$84.02
$94.62
52-Wochen-Spanne:
Value
$53.56
$94.62

Incyte Corp Stock (INCY) Company Profile

Name
Firmenname
Incyte Corp
Name
Telefon
(302) 498-6700
Name
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
Mitarbeiter
2,617
Name
Twitter
@Incyte
Name
Nächster Verdiensttermin
2025-02-10
Name
Neueste SEC-Einreichungen
Name
INCY's Discussions on Twitter

Vergleichen Sie INCY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
INCY
Incyte Corp
92.59 17.70B 4.58B 870.87M 945.58M 4.3988
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
419.89 106.97B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
654.04 68.62B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
449.56 63.13B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
820.36 50.61B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
194.22 35.29B 398.11M -1.03B -868.57M -5.7032

Incyte Corp Stock (INCY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-10-08 Herabstufung Oppenheimer Outperform → Perform
2025-08-06 Hochstufung Wells Fargo Equal Weight → Overweight
2025-08-01 Eingeleitet Barclays Overweight
2025-06-16 Hochstufung Stifel Hold → Buy
2025-03-18 Herabstufung Guggenheim Buy → Neutral
2025-03-18 Herabstufung William Blair Outperform → Mkt Perform
2024-12-17 Eingeleitet UBS Neutral
2024-10-29 Hochstufung BofA Securities Neutral → Buy
2024-10-01 Eingeleitet Wolfe Research Outperform
2024-09-18 Herabstufung Truist Buy → Hold
2024-07-02 Herabstufung BMO Capital Markets Market Perform → Underperform
2024-05-23 Eingeleitet Deutsche Bank Hold
2024-04-23 Eingeleitet Cantor Fitzgerald Neutral
2024-02-23 Eingeleitet Jefferies Buy
2024-02-14 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2023-12-13 Hochstufung Leerink Partners Market Perform → Outperform
2023-12-04 Hochstufung Guggenheim Neutral → Buy
2023-11-21 Herabstufung Goldman Buy → Neutral
2023-07-25 Eingeleitet Citigroup Buy
2023-05-04 Herabstufung BofA Securities Buy → Neutral
2023-04-10 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2023-03-24 Hochstufung SVB Securities Underperform → Market Perform
2023-01-31 Eingeleitet Piper Sandler Overweight
2022-08-03 Herabstufung Evercore ISI Outperform → In-line
2022-08-03 Herabstufung Guggenheim Buy → Neutral
2022-07-28 Eingeleitet Wells Fargo Equal Weight
2022-02-09 Herabstufung SVB Leerink Mkt Perform → Underperform
2022-01-18 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2021-11-19 Eingeleitet BMO Capital Markets Market Perform
2021-07-20 Hochstufung The Benchmark Company Hold → Buy
2021-02-10 Herabstufung SVB Leerink Mkt Perform → Underperform
2021-01-07 Eingeleitet Truist Buy
2021-01-04 Hochstufung Guggenheim Neutral → Buy
2020-06-16 Eingeleitet The Benchmark Company Hold
2020-05-06 Herabstufung JP Morgan Overweight → Neutral
2020-04-29 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-04-01 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-03-24 Fortgesetzt William Blair Outperform
2020-03-13 Hochstufung BofA/Merrill Neutral → Buy
2020-02-04 Fortgesetzt BofA/Merrill Neutral
2020-01-03 Bestätigt BMO Capital Markets Market Perform
2020-01-03 Herabstufung Mizuho Buy → Neutral
2020-01-02 Herabstufung Guggenheim Buy → Neutral
2019-10-03 Eingeleitet Mizuho Buy
2019-09-12 Eingeleitet BMO Capital Markets Market Perform
2019-09-05 Hochstufung JMP Securities Mkt Perform → Mkt Outperform
2019-09-05 Fortgesetzt Morgan Stanley Equal-Weight
2019-09-05 Hochstufung Oppenheimer Perform → Outperform
2019-05-21 Eingeleitet Credit Suisse Neutral
2019-05-03 Herabstufung Barclays Overweight → Equal Weight
2019-04-11 Eingeleitet Stifel Hold
2019-04-03 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2019-01-24 Hochstufung William Blair Mkt Perform → Outperform
Alle ansehen

Incyte Corp Aktie (INCY) Neueste Nachrichten

pulisher
12:24 PM

Decoding Incyte Corp (INCY): A Strategic SWOT Insight - GuruFocus

12:24 PM
pulisher
12:11 PM

Can Incyte Corporation stock hit record highs againWeekly Trade Review & Expert Verified Stock Movement Alerts - newser.com

12:11 PM
pulisher
Oct 30, 2025

Incyte Corp (INCY) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada

Oct 30, 2025
pulisher
Oct 30, 2025

Incyte Corporation (INCY) Stock Forecasts - Yahoo! Finance Canada

Oct 30, 2025
pulisher
Oct 30, 2025

Incyte Corp (INCY) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo! Finance UK

Oct 30, 2025
pulisher
Oct 30, 2025

Incyte's (INCY) Hold Rating Reiterated at Truist Financial - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Incyte (INCY) Gains Exclusive Distribution Rights for Tafasitamab in Latin America - GuruFocus

Oct 30, 2025
pulisher
Oct 30, 2025

Incyte to Present at Upcoming Investor Conferences - Yahoo Finance

Oct 30, 2025
pulisher
Oct 30, 2025

Transcend Capital Advisors LLC Makes New $437,000 Investment in Incyte Corporation $INCY - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Multi asset correlation models including Incyte CorporationMarket Risk Report & Fast Gain Stock Trading Tips - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Will Incyte Corporation (ICY) stock return to pre crash levels2025 Bull vs Bear & Daily Growth Stock Investment Tips - newser.com

Oct 30, 2025
pulisher
Oct 30, 2025

Can Incyte Corporation stock deliver sustainable ROELayoff News & Safe Entry Point Alerts - newser.com

Oct 30, 2025
pulisher
Oct 29, 2025

Can Incyte Corporation (ICY) stock attract analyst upgradesOil Prices & Daily Momentum Trading Reports - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch

Oct 29, 2025
pulisher
Oct 29, 2025

RBC Capital Raises Incyte (INCY) Price Target to $84 | INCY Stoc - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Incyte (INCY) Rating Reiterated and Price Target Raised by Truis - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Wells Fargo Raises Incyte (INCY) Price Target to $97.00 | INCY S - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Incyte (INCY): Barclays Raises Price Target to $101 with Overwei - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Incyte Corporation (NASDAQ:INCY) Q3 2025 Earnings Call Transcript - Insider Monkey

Oct 29, 2025
pulisher
Oct 29, 2025

Incyte Corporation $INCY Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat

Oct 29, 2025
pulisher
Oct 29, 2025

How Incyte Corporation stock responds to policy changes2025 Valuation Update & Safe Capital Growth Tips - newser.com

Oct 29, 2025
pulisher
Oct 29, 2025

INCY Q3 Deep Dive: Strong Product Momentum and Pipeline Reshaping Amid Strategic Refocus - Yahoo! Finance Canada

Oct 29, 2025
pulisher
Oct 29, 2025

How Investors Are Reacting To Incyte (INCY) Surging Q3 Earnings and Promising Late-Stage Trial Data - Yahoo! Finance Canada

Oct 29, 2025
pulisher
Oct 28, 2025

Incyte: Q3 Earnings Snapshot - Stamford Advocate

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte (NASDAQ:INCY) Hits New 12-Month HighWhat's Next? - MarketBeat

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Walloped Third-Quarter Profit Views. Why Shares Fell. - Investor's Business Daily

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms - Benzinga

Oct 28, 2025
pulisher
Oct 28, 2025

1 Growth Stock Under $100 to Buy Before It Soars - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Bank of America Securities Maintains a Buy on Incyte Corporation (INCY) - Insider Monkey

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte (INCY) Sees Strong Growth with Key Products and Raises Gu - GuruFocus

Oct 28, 2025
pulisher
Oct 28, 2025

Why Incyte (INCY) Stock Is Trading Lower Today - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte stock price target raised to $109 by BofA on strong Jakafi sales - Investing.com

Oct 28, 2025
pulisher
Oct 28, 2025

INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales - TradingView

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Raises Sales Targets But Investors Aren’t Cheering - Finimize

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte (INCY) PT Raised to $109 at BofA Securities - StreetInsider

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Q3 2025 slides: Revenue jumps 20% as product portfolio expands - Investing.com

Oct 28, 2025
pulisher
Oct 28, 2025

Earnings call transcript: Incyte Q3 2025 beats forecasts, stock surges - Investing.com

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte (INCY) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Outpaces Expectations And Raises Its Revenue Forecast - Finimize

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte (INCY) Boosts 2025 Revenue Forecast on Strong Product Dem - GuruFocus

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Corporation (INCY) Q3 FY2025 earnings call transcript - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates - BioSpace

Oct 28, 2025
pulisher
Oct 28, 2025

Why Incyte Corporation (ICY) stock stays resilientWeekly Market Report & Growth Focused Stock Pick Reports - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte Corp (INCY) Q3 2025 Earnings: EPS of $2.11 Beats Estimates, Revenue Surges to $1.37 Billion - GuruFocus

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte shares rise as third quarter results beat expectations, guidance raised By Investing.com - Investing.com South Africa

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte shares rise as third quarter results beat expectations, guidance raised - Investing.com

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte releases new data from Phase IIIb trial of Opzelura in dermatitis - The Pharma Letter

Oct 28, 2025
pulisher
Oct 28, 2025

Incyte earnings beat by $0.67, revenue topped estimates - Investing.com

Oct 28, 2025
pulisher
Oct 28, 2025

Drugmaker Incyte tops Q3 revenue estimates, raises guidance - TradingView

Oct 28, 2025

Finanzdaten der Incyte Corp-Aktie (INCY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$28.67
price down icon 0.97%
$36.94
price up icon 0.74%
$104.67
price up icon 1.28%
biotechnology ONC
$308.22
price down icon 2.11%
$194.22
price up icon 16.33%
Kapitalisierung:     |  Volumen (24h):